Description
Ikarugamycin is an antibiotic initially produced by species of Streptomyces that exhibits antibacterial, anti-protozoal, and anticancer activities. Ikarugamycin prevents formation of the bacterial 70S ribosomal subunit, inhibiting protein translation. In vitro, ikarugamycin inhibits CCP-dependent phagocytosis, preventing PMA-induced downregulation of CD4. Additionally, ikarugamycin inhibits uptake of oxidized LDL, preventing accumulation of cholesterol ester in macrophages.
References
Popescu R, Heiss EH, Ferk F, et al. Ikarugamycin induces DNA damage, intracellular calcium increase, p38 MAP kinase activation and apoptosis in HL-60 human promyelocytic leukemia cells. Mutat Res. 2011 May 10;709-710:60-6. PMID: 21392513.
Luo T, Fredericksen BL, Hasumi K, et al. Human immunodeficiency virus type 1 Nef-induced CD4 cell surface downregulation is inhibited by ikarugamycin. J Virol. 2001 Mar;75(5):2488-92. PMID: 11160755.
Hasumi K, Shinohara C, Naganuma S, et al. Inhibition of the uptake of oxidized low-density lipoprotein in macrophage J774 by the antibiotic ikarugamycin. Eur J Biochem. 1992 Apr 15;205(2):841-6. PMID: 1572375.
Jomon K, Kuroda Y, Ajisaka M, et al. A new antibiotic, ikarugamycin. J Antibiot (Tokyo). 1972 May;25(5):271-80. PMID: 4625358.